Kestra Advisory Services LLC Sells 963 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Kestra Advisory Services LLC reduced its stake in Thermo Fisher Scientific by 3.2%, selling 963 shares and retaining a total of 29,402 shares worth approximately $14.63 million.
• Thermo Fisher Scientific reported Q2 earnings of $5.36 EPS, exceeding analysts' expectations, with revenue of $10.86 billion and a net margin of 15.24% for the quarter.
• The company's recent dividend announcement includes a quarterly payment of $0.43 per share, reflecting an annualized yield of 0.3% and a low payout ratio of 9.95%.

Kestra Advisory Services LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,402 shares of the medical research company's stock after selling 963 shares during the quarter. Kestra Advisory Services LLC's holdings in Thermo Fisher Scientific were worth $14,630,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. D.B. Root & Company LLC increased its position in Thermo Fisher Scientific by 21.7% during the first quarter. D.B. Root & Company LLC now owns 1,120 shares of the medical research company's stock worth $557,000 after buying an additional 200 shares during the last quarter. 1832 Asset Management L.P. boosted its position in Thermo Fisher Scientific by 45.1% during the first quarter. 1832 Asset Management L.P. now owns 788,775 shares of the medical research company's stock worth $392,494,000 after purchasing an additional 245,212 shares during the period. Compound Planning Inc. lifted its position in Thermo Fisher Scientific by 52.4% during the first quarter. Compound Planning Inc. now owns 3,992 shares of the medical research company's stock worth $1,987,000 after acquiring an additional 1,373 shares during the last quarter. Bragg Financial Advisors Inc increased its stake in shares of Thermo Fisher Scientific by 4.2% during the first quarter. Bragg Financial Advisors Inc now owns 13,498 shares of the medical research company's stock worth $6,717,000 after purchasing an additional 538 shares during the period. Finally, Norinchukin Bank The lifted its holdings in Thermo Fisher Scientific by 15.0% during the 1st quarter. Norinchukin Bank The now owns 19,430 shares of the medical research company's stock worth $9,668,000 after purchasing an additional 2,531 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,896 shares of company stock valued at $13,603,438 over the last 90 days. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

TMO has been the topic of several recent research reports. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Barclays raised their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Finally, Robert W. Baird upped their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Trading Up 0.5%

NYSE TMO traded up $2.48 during trading hours on Thursday, reaching $490.60. The company's stock had a trading volume of 1,391,115 shares, compared to its average volume of 2,451,615. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market cap of $185.25 billion, a P/E ratio of 28.37, a P/E/G ratio of 2.61 and a beta of 0.74. The firm has a fifty day simple moving average of $448.63 and a 200-day simple moving average of $455.69.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the firm earned $5.37 earnings per share. The company's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.